Oramed Pharmaceuticals Inc. (ORMP.OB) to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013
4/30/2013 7:14:18 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
JERUSALEM, April 29, 2013 /PRNewswire/ --
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral delivery systems of drugs currently administered by injection, announced today that its abstract, entitled "Oral insulin capsules toward management of Type 1 diabetes mellitus," will be presented at the Global Technology Community Diabetes Summit 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by